CA-ENERO-GROUP
8.6.2021 15:02:15 CEST | Business Wire | Press release
Enero Group (ASX:EGG) has today announced the appointment of Heather Kernahan as Global Chief Executive Officer of Hotwire, the Group’s leading global technology communications consultancy. The appointment will see Kernahan report to Brent Scrimshaw, Enero Group CEO, effective 1 July 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005467/en/
Barbara Bates, who has successfully led Hotwire for the past five years, will move into a newly created senior advisory role at Enero. Bates will help facilitate Enero Group’s M&A activities in North America and will continue to report to Brent Scrimshaw.
“I would like to thank Barbara for her leadership and drive in Hotwire being the successful, global technology communications consultancy that it is today. She has been an innovative, respected and transformational leader across nearly three decades in the global communications industry. I am delighted she will remain in the Group.
“This change provides an excellent opportunity for Heather Kernahan to lead the next phase of growth for Hotwire. Heather has demonstrated incredible leadership in tackling the challenges and opportunities of a rapidly-growing business in Hotwire USA. Heather has the skills, experience and appetite for growth and her appointment demonstrates the deep bench strength of the Hotwire leadership team. I am confident she will continue to drive the business’ momentum and push Hotwire to even greater heights,” said Brent Scrimshaw.
Commenting on her appointment, Heather Kernahan said: “There is no more exciting industry to be in than technology and I’m thrilled to lead the Hotwire team as we continue to grow. We have ambitious plans to bring more value to our fast growth and global tech clients, who are looking for an alternative to the big multinational agencies. Barbara has led a culture, team and business that is sought after by the largest tech companies in the world and I’m honoured to now lead this organisation. With 20 years behind us, we feel that we’re just getting started.”
Barbara Bates said: “I’ve had the privilege to work with so many amazing people during my time at Hotwire, and I’m exceptionally proud of what we’ve managed to create together. Hotwire is already one of the world’s most highly-regarded tech communications businesses and with Heather’s leadership, it has never been better positioned to grow further. I’m excited to stay connected to the Enero Group and I look forward to continue building on the Group’s strong momentum and ambition.”
Heather Kernahan joined Hotwire from Eastwick Communications, as president of Hotwire North America and Australia, after its acquisition in 2016 by Enero Group. In 2019, she was named Hotwire CEO of North America. Under her leadership the agency has experienced record growth. With over 20 years of industry experience, Kernahan has held senior marketing and executive leadership roles at fast growth and global technology organisations including Autodesk, Enphase Energy and Alias. Under her leadership, Hotwire has developed partnerships with technology companies including: Adobe, Facebook, McAfee, Commvault, NetApp and Pinterest. As a global tech expert and business leader she has been named one of 2020 SF Business Times’ 100 Most Influential Women and is the Board Chair of The PR Council. Kernahan holds an MBA in Sustainable Enterprise from Dominican University of California.
This announcement comes as Hotwire continues to expand the team while delivering outstanding business results and following the successful acquisition of McDonald Butler Associates in London last month. In the past year, Hotwire has continued its 20 years of industry leadership, being named 2020 Global Technology Agency of the Year by PRovoke Media, Best Places to Work in PR by PRWeek for two years in a row and recently recognised as one of the Best Companies to Work for in the UK by the Sunday Times . Current clients include Accenture, Adobe, AWS, Citrix, Dell Technologies, Deloitte, Delphix, DXC Technology, eBay, GoPro, Honeywell, IBM, McAfee, Pegasystems and PWC.
About Enero:
Headquartered in Sydney, Australia, Enero Group is a boutique network of marketing and communications businesses listed on the ASX (Australian Stock Exchange) that includes creative agency BMF, PR and integrated communications agencies Hotwire and CPR, strategic data consultancies The Leading Edge and The Digital Edge, digital agency Orchard and programmatic marketing specialist OB Media. www.enero.com .
About Hotwire
Hotwire is the global technology communication consultancy. Founded in 2000, we operate a worldwide network of wholly owned offices and partners serving a range of clients from scale ups to established multi-nationals. We unleash the possibilities of innovative technology through integrated communications that ignite curiosity, spark action and fuel success. We do this using our proprietary methodology which is underpinned by robust insight and strategy, purposeful creative, integrated planning and a core emphasis on measurement and evaluation. www.hotwireglobal.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005467/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
